Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis

Abstract

Background: Several clinical guidelines recommend the use of proton pump inhibitors (PPIs) in patients taking low-dose aspirin but report no or limited supporting data. We conducted a systematic review and meta-analysis to examine the effects of co-administration of PPIs in patients taking low-dose aspirin on the risks of adverse gastrointestinal (GI) and cardiovascular (CV) events, and on patient adherence to aspirin. Methods: We searched PUBMED, EMBASE and Cochrane Central Register of Controlled Trials databases for relevant articles published through November 2013. We included randomised controlled trials (RCTs) and observational studies in patients taking low-dose aspirin with and without PPIs. Risk of bias was assessed using the Cochrane Collaboration's tool (for RCTs) and the Newcastle-Ottawa Scale (for observational studies). Pooled risk ratios (RRs) were computed using a random-effects model. Results: We included 13 studies, of which 12 (2 RCTs and 10 observational studies) reported on GI events, and one (cohort study) on both GI bleeding and CV events. No study reported on adherence to aspirin. Co-administration of PPIs in patients receiving low-dose aspirin was associated with risk reductions of 73% (RR 0.27, 95% CI 0.17-0.42) and 50% (RR 0.50, 95% CI 0.32-0.80) in the occurrence of peptic ulcer and GI bleeding respectively. There was evidence of bias in publications reporting on the GI events. Conclusions: The practice of co-prescribing PPIs in patients taking lowdose aspirin is supported by some data, but the evidence is rather weak. It currently remains unclear whether the benefits of co-administration of PPIs in users of low-dose aspirin outweigh their potential harms. Review criteria• Randomised controlled trials (RCTs) and observational studies in patients receiving lowdose aspirin.• Studies reporting on adverse gastrointestinal or cardiovascular events, or adherence to aspirin.

Multimorbidity and polypharmacy in diabetic patients with NAFLD

“…PPIs block gastric acid secretion and are widely used for treating gastroesophageal reflux disease (GORD), peptic ulcer disease and for prevention of low-dose aspirin-induced ulcers. [44] The specific indications for PPI prescriptions could not be addressed in our study. Of the patients prescribed a PPI, only 7 patients reported a history of GORD and 65% were also prescribed an antiplatelet agent or anticoagulant.…”

Effects of Inappropriate Acetylsalicylic Acid Use on Non-fatal Bleedings

“…There are limited data about PPI use for decreasing the risks of GI bleeding events in patients on long-term ASA therapy. PPIs had potential benefit of decreasing low-dose ASA-associated upper GI ulcers and bleeding events (25). In our study groups, the rate of concomitant PPI use was 41.9%, 57.4% and 46.6%, respectively, but these levels did not affect GI bleeding event rates.…”

Direct Medical Cost Analysis Among Coronary Heart Disease and Heart Failure Outpatients at One Hospital

“…Concerns about bleeding can be anticipated with the use of drugs with proton-pump inhibitors 18,19 . In a meta-analysis, Tran-Duy et al (2015) prove that the provision of proton pump inhibitors can reduce the risk of gastrointestinal bleeding by 50% (RR 0.5; 95% CI 0.32-0.80) 20 .…”